Dr. Gregory T. Everson
Fellow of the American College of Physicians
Fellow of the American Gastroenterological Association

Gregory T. Everson, MD
Professor of Medicine
Division of Gastroenterology & Hepatology
University of Colorado School of Medicine

Dr. Everson received his MD degree from Cornell Medical College, NY, NY and is currently Professor of Medicine and Director of Hepatology at the University of Colorado, Denver. Dr. Everson has published over 300 original papers, books, and book chapters in peer-reviewed journals that include Hepatology, Clinics in Liver Disease, Gastroenterology, Journal of Hepatology, New England Journal of Medicine, The American Journal of Gastroenterology, Alimentary Pharmacology and Therapeutics, and Expert Reviews in Gastroenterology and Hepatology. In conjunction with Hedy Weinberg, he has co-authored 4 editions of the popular “self-help” book, Living with Hepatitis C: A Survivor’s Guide, for patients and families. He is a frequent invited speaker and has presented his work at clinical and scientific meetings nationally and internationally. He is a principal investigator for the HALT-C trial (Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis) for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH), and numerous other clinical trials. Dr. Everson is a member of the American Association for the Study of Liver Diseases (AASLD), the American Society of Transplantation, the International Liver Transplant Society, and the International Association for the Study of the Liver. In addition he is a member of both the Transplant Hepatology Committee of the American Board of Internal Medicine, and the standing panel for accreditation appeals in the specialty of Internal Medicine/Transplant Hepatology of the Accreditation Council for Graduate Medical Education.

HepQuant Fact

All the major manifestations of liver disease, such as ascites, varices, and encephalopathy, are related to an altered portal circulation. HepQuant-Dual was designed to assess the portal circulation – test parameters are continuous variables that may be correlated to clinical features or may be followed over time to measure disease progression. HepQuant-Dual is non-invasive, uses stable (not radioactive) isotopes, and relies on natural, well-defined hepatic functions to measure the portal circulation.

Liver Disease Fact

• Approximately 10 million people suffer from chronic liver disease in the United States.
• Approximately 500 million people suffer from chronic liver disease globally.
• The most common chronic liver diseases are Hepatitis B, Hepatitis C, Non-alcoholic Steatohepatitis (NASH), Alcoholic Liver Disease (Laennec’s cirrhosis), and Autoimmune diseases (Autoimmune hepatitis, Primary Biliary Cirrhosis, and Primary Sclerosing Cholangitis)

For More Information

Professional Organizations
1. American Association for the Study of Liver Disease (AASLD)
2. American Gastroenterological Association (AGA)
3. European Association for the Study of the Liver (EASL)
4. Asian Pacific Association for the Study of the Liver (APASL)

Patient Support Groups
1. Caring Ambassadors Program
2. Hep C Connection
3. American Liver Foundation
4. PSC Partners for Cure